Boardroom Alpha
Boardroom Alpha
SLDB · Additional Proxy Materials (DEFA14A) · Filed April 23, 2026

Solid Biosciences Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 23, 2026
Ticker
SLDB
Accession
0001193125-26-173684
Boardroom Alpha · Filing insights

Solid Biosciences' 2026 proxy: board slate, new director, share authorization increase; board backs all proposals.

About Solid Biosciences Inc
Market cap
$648M
1Y TSR
+59.3%
3Y TSR
+5.3%
Board grade
D
Sector
Healthcare
CEO
Alexander Cumbo
Last annual meeting: Jun 10, 2026 · View full Solid Biosciences Inc profile →
DEFA14A

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material under §240.14a-12

SOLID BIOSCIENCES INC.

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

No fee required

Fee paid previously with preliminary materials

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


img217070638_0.jpg

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON JUNE 10, 2026 Your Vote Counts! SOLID BIOSCIENCES INC. 2026 Annual Meeting June 10, 2026 8:00 AM Eastern Time Virtual Meeting Site: www.virtualshareholdermeeting.com/SLDB2026SOLID BIOSCIENCES INC. C/O PROXY SERVICES P.O. BOX 9142 FARMINGDALE, NY 11735 You invested in SOLID BIOSCIENCES INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 27, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote in Advance of the Meeting Vote by June 9, 2026 11:59 PM ET Visit www.ProxyVote.com Vote Virtually at the Meeting* June 10, 2026 8:00 AM Eastern Time Visit: www.virtualshareholdermeeting.com/SLDB2026*Please check the meeting materials for any special requirements for meeting attendance.


img217070638_1.jpg

Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. We encourage you to access and review all of the important information contained in the proxy materials before voting. Please follow the instructions on the reverse side to vote these important matters. Voting Items 1. Election of Class II Directors Nominees: 1a. Clare Kahn 1b. Adam Stone 1c. Lynne Sullivan 2. The ratification of the appointment of Ilan Ganot, on an advisory basis, to the Company’s Board of Directors as a Class I Director to hold office until the 2028 annual meeting of stockholders. 3. The ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. 4. The approval of an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company’s common stock from 240,000,000 to 480,000,000. 5. The approval of an advisory vote on executive compensation. NOTE: The proxies are authorized to vote, in their discretion, upon such other business as may properly come before the meeting or any adjournment or postponement thereof. Board Recommends For For For For For For For Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.


From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Solid Biosciences Inc (SLDB)

Reference

Frequently asked questions

When did Solid Biosciences Inc file this DEFA14A?
Solid Biosciences Inc (SLDB) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 23, 2026. The accession number assigned by EDGAR is 0001193125-26-173684.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Solid Biosciences' 2026 proxy: board slate, new director, share authorization increase; board backs all proposals. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Solid Biosciences Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Solid Biosciences Inc has filed under CIK 1707502, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer